- Home
- TECX vs EDD Comparison
TECX vs EDD Comparison
Compare TECX & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- EDD
- Stock Information
- Founded
- TECX 2019
- EDD 2007
- Country
- TECX United States
- EDD United States
- Employees
- TECX N/A
- EDD N/A
- Industry
- TECX
- EDD Finance Companies
- Sector
- TECX
- EDD Finance
- Exchange
- TECX Nasdaq
- EDD Nasdaq
- Market Cap
- TECX 387.1M
- EDD 329.4M
- IPO Year
- TECX 2018
- EDD N/A
- Fundamental
- Price
- TECX $23.51
- EDD $5.33
- Analyst Decision
- TECX Strong Buy
- EDD
- Analyst Count
- TECX 5
- EDD 0
- Target Price
- TECX $79.00
- EDD N/A
- AVG Volume (30 Days)
- TECX 230.2K
- EDD 254.3K
- Earning Date
- TECX 08-07-2025
- EDD 01-01-0001
- Dividend Yield
- TECX N/A
- EDD 7.52%
- EPS Growth
- TECX N/A
- EDD N/A
- EPS
- TECX N/A
- EDD N/A
- Revenue
- TECX N/A
- EDD N/A
- Revenue This Year
- TECX N/A
- EDD N/A
- Revenue Next Year
- TECX N/A
- EDD N/A
- P/E Ratio
- TECX N/A
- EDD N/A
- Revenue Growth
- TECX N/A
- EDD N/A
- 52 Week Low
- TECX $13.70
- EDD $4.22
- 52 Week High
- TECX $61.07
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- TECX 56.50
- EDD 67.29
- Support Level
- TECX $21.31
- EDD $5.06
- Resistance Level
- TECX $23.12
- EDD $5.31
- Average True Range (ATR)
- TECX 1.53
- EDD 0.05
- MACD
- TECX 0.13
- EDD 0.02
- Stochastic Oscillator
- TECX 71.85
- EDD 90.39
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.